L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder
The lack of biomarkers greatly limits the diagnosis and treatment of major depressive disorder (MDD). Endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play antidepressant roles by improving brain energy metabolism, regulating neurotransmitters and neural plasticity. The levels...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.671151/full |
id |
doaj-c3f7e4379c84474691504281b8b1fc91 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li-Juan Nie Li-Juan Nie Li-Juan Nie Li-Juan Nie Jun Liang Jun Liang Jun Liang Jun Liang Feng Shan Feng Shan Feng Shan Feng Shan Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia |
spellingShingle |
Li-Juan Nie Li-Juan Nie Li-Juan Nie Li-Juan Nie Jun Liang Jun Liang Jun Liang Jun Liang Feng Shan Feng Shan Feng Shan Feng Shan Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder Frontiers in Psychiatry biomarker acetyl-l-carnitine diagnosis depression L-Carnitine |
author_facet |
Li-Juan Nie Li-Juan Nie Li-Juan Nie Li-Juan Nie Jun Liang Jun Liang Jun Liang Jun Liang Feng Shan Feng Shan Feng Shan Feng Shan Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Bao-Shi Wang Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Yuan-Yuan Mu Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Xie-Hai Zhou Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia Qing-Rong Xia |
author_sort |
Li-Juan Nie |
title |
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder |
title_short |
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder |
title_full |
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder |
title_fullStr |
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder |
title_full_unstemmed |
L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder |
title_sort |
l-carnitine and acetyl-l-carnitine: potential novel biomarkers for major depressive disorder |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Psychiatry |
issn |
1664-0640 |
publishDate |
2021-09-01 |
description |
The lack of biomarkers greatly limits the diagnosis and treatment of major depressive disorder (MDD). Endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play antidepressant roles by improving brain energy metabolism, regulating neurotransmitters and neural plasticity. The levels of ALC in people and rodents with depression are significantly reduced. It is necessary to determine whether serum LC and ALC might be used as novel biomarkers for the diagnosis of MDD. Here, ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to determine the concentration of LC and ALC in the serum of healthy controls and patients with MDD; among the latter, in patients who were responsive (effective group) and non-responsive (ineffective group) after 2 weeks of treatment. The diagnostic value of serum LC and ALC for MDD was assessed. Compared with healthy controls, the serum LC and ALC concentrations in patients with MDD were significantly decreased (P < 0.001). Pearson correlation analysis shows that the HDRS-24 score was negatively associated with serum ALC (r = −0.325, P = 0.007). Receiver operating characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.801 with 83.1% sensitivity and 66.3% specificity for LC, and an AUC of 0.898 with 88.8% sensitivity and 76.4% specificity for ALC, differentiating patients with MDD from healthy controls. Furthermore, the concentration of LC and ALC in patients with depression was significantly increased in the effective treatment group, and no significant change was observed in the ineffective treatment group. These results suggest that serum LC and ALC may be novel biomarkers for the diagnosis of MDD. |
topic |
biomarker acetyl-l-carnitine diagnosis depression L-Carnitine |
url |
https://www.frontiersin.org/articles/10.3389/fpsyt.2021.671151/full |
work_keys_str_mv |
AT lijuannie lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT lijuannie lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT lijuannie lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT lijuannie lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT junliang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT junliang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT junliang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT junliang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT fengshan lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT fengshan lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT fengshan lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT fengshan lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT baoshiwang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT baoshiwang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT baoshiwang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT baoshiwang lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT yuanyuanmu lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT yuanyuanmu lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT yuanyuanmu lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT yuanyuanmu lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT xiehaizhou lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT xiehaizhou lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT xiehaizhou lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT xiehaizhou lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT qingrongxia lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT qingrongxia lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT qingrongxia lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder AT qingrongxia lcarnitineandacetyllcarnitinepotentialnovelbiomarkersformajordepressivedisorder |
_version_ |
1716863966009884672 |
spelling |
doaj-c3f7e4379c84474691504281b8b1fc912021-09-30T05:27:04ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402021-09-011210.3389/fpsyt.2021.671151671151L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive DisorderLi-Juan Nie0Li-Juan Nie1Li-Juan Nie2Li-Juan Nie3Jun Liang4Jun Liang5Jun Liang6Jun Liang7Feng Shan8Feng Shan9Feng Shan10Feng Shan11Bao-Shi Wang12Bao-Shi Wang13Bao-Shi Wang14Bao-Shi Wang15Yuan-Yuan Mu16Yuan-Yuan Mu17Yuan-Yuan Mu18Yuan-Yuan Mu19Xie-Hai Zhou20Xie-Hai Zhou21Xie-Hai Zhou22Xie-Hai Zhou23Qing-Rong Xia24Qing-Rong Xia25Qing-Rong Xia26Qing-Rong Xia27Affiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaAffiliated Psychological Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pharmacy, Hefei Fourth People's Hospital, Hefei, ChinaPsychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei, ChinaAnhui Clinical Research Center for Mental Diseases, Hefei, ChinaThe lack of biomarkers greatly limits the diagnosis and treatment of major depressive disorder (MDD). Endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play antidepressant roles by improving brain energy metabolism, regulating neurotransmitters and neural plasticity. The levels of ALC in people and rodents with depression are significantly reduced. It is necessary to determine whether serum LC and ALC might be used as novel biomarkers for the diagnosis of MDD. Here, ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to determine the concentration of LC and ALC in the serum of healthy controls and patients with MDD; among the latter, in patients who were responsive (effective group) and non-responsive (ineffective group) after 2 weeks of treatment. The diagnostic value of serum LC and ALC for MDD was assessed. Compared with healthy controls, the serum LC and ALC concentrations in patients with MDD were significantly decreased (P < 0.001). Pearson correlation analysis shows that the HDRS-24 score was negatively associated with serum ALC (r = −0.325, P = 0.007). Receiver operating characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.801 with 83.1% sensitivity and 66.3% specificity for LC, and an AUC of 0.898 with 88.8% sensitivity and 76.4% specificity for ALC, differentiating patients with MDD from healthy controls. Furthermore, the concentration of LC and ALC in patients with depression was significantly increased in the effective treatment group, and no significant change was observed in the ineffective treatment group. These results suggest that serum LC and ALC may be novel biomarkers for the diagnosis of MDD.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.671151/fullbiomarkeracetyl-l-carnitinediagnosisdepressionL-Carnitine |